Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp181 | Cell biology: osteoblasts and bone formation | ECTS2013

The impairement of bone formation and mineralization in BSP−/− mouse calvaria cell cultures is partly rescued by increasing cell density

Bouet Guenaelle , Bouleftour Wafa , David Marchat , Marie-Therese Linossier , Mireille Thomas , Jane Aubin E , Laurence Vico , Luc Malaval

Bone sialoprotein regulates osteoblast activity and bone formation. In knockout (BSP−/−) mouse bone marrow (BM) stromal cell cultures, the pool of osteoprogenitor (OP) cells (CFU-F number) is not different from wild-type (+/+), nor is their early differentiation (same numbers of alkaline phosphatase positive colonies=CFU-ALP, although these are smaller), while the number of osteoblast, mineralized colonies (CFU-OB) is dramatically reduced. Because ossifi...

ba0002p172 | (1) | ICCBH2013

Longitudinal assessment of spinal bone mineral density in children with neurofibromatosis type 1 using dual energy absorptiometry and quantitative computed tomography

Eelloo Judith , Ward Kate , Huson Susan M , Adams Judith E , Russell Sarah , Wright Naville , Evans Gareth , Mughal M Zulf

Aim: Scoliosis is a common skeletal problem affecting 10–30% of patients with neurofibromatosis type 1 (NF1). NF1 patients have been shown to have reduced bone mineral density (BMD) which may play a role in the pathogenesis or progression of scoliosis. Our centre is one of four international centres currently evaluating the efficacy of various spinal imaging techniques and BMD as predictors for scoliosis in NF1. In our cohort we measured the lumbar spine (LS) BMD both by ...

ba0003oc4.6 | Genetics of bone disease | ECTS2014

Gout is associated with an excess risk of osteoporotic fracture: findings from a Danish registry

Dennison Elaine , Rubin Katrine H , Harvey Nick , Walker-Bone Karen E , Schwarz Peter , Cooper Cyrus , Abrahamsen Bo

Objective: Although metabolic syndrome is common in gout patients, recent reports that bone mineral density may actually be reduced (and falls common) in this group have led researchers to hypothesise that osteoporotic fracture may be more common in subjects with gout than in healthy controls. We tested this hypothesis in a national Danish registry.Material and Methods: We identified subjects as new users of allopurinol, a proxy for gout, for the years 1...

ba0003pp103 | Cancer and bone: basic, translational and clinical | ECTS2014

Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle

Lamoureux Francois , Baud'huin Marc , Calleja Lidia Rodriguez , Jacques Camille , Redini Francoise , Lecanda Fernando , Bradner James E. , Heymann Dominique , Ory Benjamin

The vicious cycle established between bone associated tumors and bone resorption is the central problem with therapeutic strategies against primary bone tumors and bone metastasis. The bromodomain and extra-terminal domain (BET) protein family is an important class of ‘histone reading protein’ capable to recognize the N-acetylation of lysine residues on histone tails. BET bromain proteins have recently been described as regulators of MYC expression in various tumors....

ba0003lb2 | (1) | ECTS2014

Bisphosphonates for osteoporosis and risk of breast cancer: misleading results from observational studies

Cummings Steven R , Hue Trisha , Cauley Jane A , Bauer Doug C , Ensrud Kristine E , Barrett-Connor Elizabeth , Black Dennis M

Purpose: To test whether bisphosphonates for osteoporosis reduce the risk of breast cancer.Background: Observational studies and meta-analyses find that women taking bisphosphonates have about a 1/3rd reduction in risk of breast cancer as soon as 1 year of treatment. This is plausible because bisphosphonates have in vitro anti-tumor activity and high doses of zoledronate reduce recurrence in women with breast cancer. However, observational studi...

ba0005oc5.5 | Risk factors for fracture, Pagets disease of bone and musle and bone | ECTS2016

The relationship between muscle strength and bone outcomes in ageing UK men

Zengin Ayse , Pye Stephen R , Cook Michael J , Adams Judith E , Wu Frederick C W , O'Neill Terrence W , Ward Kate A

Morbidity and mortality are associated with osteoporosis and sarcopenia. There are few data describing the associations between functional measures of muscle and bone. Therefore, the aim of this study was to examine the associations of muscle strength and tibial bone outcomes in ageing men.Men (n=301) aged 40–85 years were recruited in UK (201-White, 43-Black, 57-South-Asian). pQCT was performed at the 38 and 66% tibia with the outcome meas...

ba0006p137 | (1) | ICCBH2017

Growth, bone and muscle mass are adversely affected in bone marrow transplant recipients: a body composition analysis

Doulgeraki Artemis , Vlachopapadopoulou E , Peristeri I , Paisiou A , Polizois G , Kaisari K , Monopolis I , Vessalas G , Michalacos S , Kitra V

Objectives: There are many factors leading to poor bone health and imbalanced body composition in bone marrow transplant (BMT) recipients. We aimed to report our patients’ profile and to correlate it with clinical parameters.Methods: Cross-sectional study of paediatric BMT patients. Assessment of growth (height, weight, BMI) and dual-energy X-ray absorptiometry (DXA) for evaluation of bone mineral density (BMD) and geometry, muscle and fat mass. All...

ba0005ht5 | (1) | ECTS2016

Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study

Langdahl B , Libanati C , Crittenden D B , Bolognese M A , Brown J P , Daizadeh N S , Dokoupilova E , Engelke K , Finkelstein J S , Genant H K , Goemaere S , Hyldstrup L , Jodar-Gimeno E , Keaveny T M , Kendler D , Lakatos P , Maddox J , Malouf J , Massari F E , Molina J F

STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or TPTD for 12 months in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy (NCT01796301). This study enrolled women with postmenopausal osteoporosis who had taken an oral bisphosphonate for ≥3 years prior to screening and alendronate in the year prior to screening; had a BMD T-score ≤−2.5 at the total hip (TH), lumbar spine (LS), or femoral neck (FN);...

ba0004lb2 | (1) | ICCBH2015

Recessive osteogenesis imperfecta caused by missense mutations in SPARC

Mendoza Roberto , Fahiminiya Somayyeh , Majewski Jacek , Consortium Care4Rare Canada , Tetreault Martine , Nadaf Javad , Kannu Peter , Sochett Etienne , Howard Andrew , Stimec Jennifer , Dupuis Lucie , Roschger Paul , Klaushofer Klaus , Palomo Telma , Ouellet Jean , Al-Jallad Hadil , Mort John , Moffatt Pierre , Boudko Sergei , Bachinger Hans-Peter , Rauch Frank

Objectives: We sought to identify the disease-causing mutations in two unrelated girls with a clinical diagnosis of osteogenesis imperfecta type IV.Methods: Whole-exome sequencing and cellular studies in skin fibroblasts were conducted.Results: We identified two homozygous variants in SPARC (NM_003118.3; c.497G>A (p.Arg166His) in individual 1; c.787G>A (p.Glu263Lys) in individual 2). Secreted protein, acidic, cyste...